Trial Profile

Phase II Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
Indications Malignant-mesothelioma
Focus Therapeutic Use
Acronyms MesoMab

Most Recent Events

06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
07 Feb 2017 Status changed from recruiting to completed.
04 Dec 2014 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com